arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

TELA Bio, Inc.

TELA
$0.84 ▼ -0.02 (-2.30%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
35 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

TELA Bio, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $48.1M
Dividend Yield
Revenue Growth 2.9%
Op. Margin -55.2%
ROIC -20.9%
FCF / Share $-0.20
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -10.74
info Valuation on last close. End-of-day price, Aug 7, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$19.06M
↑ +2.9%
Net Income Profit after all expenses
$-12.27M
↓ -9.0%
Operating Margin Operating profit as % of sales
-55.2%
↓ -73.4% 6th
FCF / Share Free cash flow per share
$-0.20
↑ +8.5%
Long-Term Debt Long-term obligations
$55.87M
— +0.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
6
Financial Health
18
Cash Quality
50

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 35 quarters